Prevention of human papillomavirus in Australia Australian Goverment. Department of Health and Ageing Recommendations made by the Pharmaceutical Benefits Advisory Committee (PBAC) in November 2011 relating to the list of drugs on the Pharmaceutical Benefits Scheme NOVEMBER 2011 PBAC MEETING OUTCOMES – Positive Recommendations DRUG AND FORM QUADRIVALENT HUMAN PAPILLOMAVIRUS (TYPES 6, 11, 16, 18) recombinant vaccine, solution for injection, 0.5 mL, solution for injection pre-filled syringe single dose, Gardasil® CSL Limited DRUG USE AND TYPE Vaccine for prevention of human papillomavirus LISTING REQUESTED BY SPONSOR Resubmission for extension of the current listing of Gardasil on the National Immunisation Program (NIP) to include prevention of human papillomavirus (HPV) in males 12 – 13 years of age and a catch-up program over 2 years for Year 9 males. PBAC RECOMMENDATION The PBAC recommended extension of the National Immunisation Program listing of quadrivalent human papillomavirus (types 6, 11, 16, 18) (HPV) recombinant vaccine, solution for injection 0.5 mL, to include ongoing administration to males approximately twelve to thirteen years of age in a school-based program and for two catch-up cohorts for all males in the two year groups above the ongoing cohort, delivered over two years for Year 9 males, on the basis of acceptable cost effectiveness compared with female-only vaccination. Источник: http://www.health.gov.au/internet/main/publishing.nsf/Content/pbacrec-nov11-positive |